Advanced Search

 

Study ID Status Title Patient Level Data
207927 Completed PGx7683_Exploratory PGx analysis for GSK1325760 (Ambrisentan) in 112565
207933 Active, not recruiting PGx7684: Confirmatory pharmacogenetic study investigating IL13 association with efficacy response to fluticasone furoate/vilanterol in asthma study 201378
207935 Not yet recruiting PGx7685:Exploratory PGx evaluation of adverse events observed in subjects treated with GSK3342830 in 204847 Part 2
207941 Not yet recruiting Meta-Analysis Plan for MID207941: A Study to Evaluate Risk Factors for Pneumonia and Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in a COPD Population of Patients Treated with GW685698 + GW642444 (Fluticasone Furoate + Vilanterol); GW642444 (Vilanterol); CCI18781 (Fluticasone Propionate); GR33343 (Salmeterol); CCI18781+ GR33343 (Fluticasone Propionate + Salmeterol) and Placebo
207943 Not yet recruiting Observational and retrospective study to collect long term follow-up real life data from the first patients treated by Nucala in France in the context of nATU
207968 Not yet recruiting Comparative Effectiveness of Umeclidinium/Vilanterol versus Tiotropium Bromide/Olodaterol
207969 Not yet recruiting Comparative Effectiveness of Umeclidinium/Vilanterol versus ICS/LABA Therapy
207972 Recruiting A double blind (sponsor open) placebo-controlled, stratified, parallel group study to evaluate the efficacy and safety of repeat doses of GSK3772847 in participants with moderate to severe asthma with allergic fungal airway disease (AFAD)
208034 Recruiting Understanding of the Patient and Caregiver Experience of Wiskott-Aldrich Syndrome (WAS)
208059 Not yet recruiting Population Pharmacokinetic Modeling of Fluticasone Furoate, Umeclidinium bromide and Vilanterol using Pooled Data from three Phase III (Fluticasone Furoate/Umeclidinium bromide/Vilanterol) studies (200812, CTT116853 and CTT116855) in adults with Chronic Pulmonary Obstructive Disease
208078 Completed A Randomized, Examiner-blind, Proof of Principal Study to Investigate the Stain and Plaque Removal Capability of Two Experimental 5% Potassium Nitrate Dentifrices in Healthy Subjects with the Propensity for Extrinsic Dental Stain
208091 Not yet recruiting Meta-analysis of studies MEA115588 and 200862 of mepolizumab (SB240563) to evaluate changes in AM PEF in severe eosinophilic asthma (eTrack Study Identifier 208091)
208099 Not yet recruiting PGx7687: Exploratory Pharmacogenetic Study to Investigate Efficacy of SB252263 Tafenoquine on relapse of P Vivax Malaria in TAF112582 and TAF115654
208108/091 Completed A phase II, double-blind, randomized study to compare the immunogenicity, safety and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ Tritanrix™-HepB/Hib2.5 to GSK Biologicals’ Tritanrix™-HepB/Hiberix™ when administered as a three-dose primary vaccination course to healthy infants at 6, 10 and 14 weeks of age. A dose of unconjugated Hib vaccine (plain PRP booster) will be administered at the age of 10 months to 50% of the subjects Study Listed on ClinicalStudyDataRequest.com
208109/220 Completed A Phase IIIb, open, randomized, controlled, multicenter study of the immunogenicity and safety of GSK Biologicals' inactivated hepatitis A vaccine administered on a 0-6 mth schedule concomitantly with Wyeth Lederle's pneumococcal conjugate vaccine in healthy children 15 months of age Study Listed on ClinicalStudyDataRequest.com
208109/231 Completed Immunogenicity & Safety of GSK Biologicals' Inactivated Hepatitis A Vaccine (Havrix™) Co-administered With Merck & Company, Inc. Measles-Mumps-Rubella Vaccine (M-M-RII) & Merck & Co Varicella Vaccine (VARIVAX™) to Children 15 Months of Age Study Listed on ClinicalStudyDataRequest.com
208109/232 Completed Immunogenicity and Safety of GSK Biologicals' Inactivated Hepatitis A Vaccine (Havrix™) co-administered With GSK Biologicals' DTaP Vaccine (Infanrix™) and Aventis Pasteur's Haemophilus b Conjugate Vaccine (ActHIB) in Healthy Children 15 months of Age Study Listed on ClinicalStudyDataRequest.com
208115 Recruiting Meta-analysis to further assess the efficacy of mepolizumab 100mg SC on selected endpoints and to further investigate the relationship between efficacy endpoints, blood eosinophils and other important subgroups
208116 Recruiting Meta-analysis to further assess the efficacy of mepolizumab 100mg subcutaneous dose on selected endpoints in subjects eligible for omalizumab treatment and other related subgroups
208125 Not yet recruiting A meta-Analysis to compare the efficacy and safety of umeclidinium/vilanterol 62.5/25mcg versus Placebo, umeclidinium/vilanterol 62.5/25mcg versus tiotropium 18mcg and umeclidinium/vilanterol 62.5/25mcg versus fluticasone propionate/salmeterol 250/50 in subjects with Chronic Obstructive Pulmonary Disease (COPD) in the elderly
208127/132 (EXT Y2) Completed Evaluate the Persistence of Immune Response of GSK Biologicals' Twinrix™ Vaccine, Administered According to a 0,6 month Schedule and a 0,1,6 month Schedule, in Healthy Children Aged Between 1-11 years at the Time of First Vaccine Dose Study Listed on ClinicalStudyDataRequest.com
208129 Completed Qualitative Research to Support Ellipta Ease-of-Use Questions in Pediatric Patients with Asthma
208129/002 Completed Study to evaluate the immunogenicity, reactogenicity and safety of GSK Biologicals' (previously SmithKline Beecham Biologicals') MPL-adjuvanted recombinant hepatitis B vaccine versus Engerix™-B, in haemodialysis patients
208129/004 Completed Study to evaluate the immunogenicity and reactogenicity of GSK Biologicals' MPL-adjuvanted recombinant hepatitis B vaccine in comparison with those of Engerix™-B in healthy adult volunteers following 2 different schedules
208129/005 Completed Study to evaluate the immunogenicity and reactogenicity of various formulations of GSK Biologicals’ (previously SmithKline Beecham Biologicals') recombinant hepatitis B vaccine with different adjuvants in healthy adult volunteers

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.